17 December 2013

ASX ANNOUNCEMENT

Nutrition and Body Composition

ImpediMed, Fonterra, University of Auckland and University of Queensland Working Together to Improve Nutritional Health

Brisbane, Australia – ImpediMed Limited (ASX: IPD) ("the Company") today announced that we are working with Fonterra, University of Auckland and University of Queensland to improve our understanding of how to assess the impact of nutrition on the composition of the body. ImpediMed has provided their next generation bioimpedance spectroscopy (BIS) device for this important initiative.

Dr Leigh Ward, University of Queensland, said “I am very excited to be leading the development of this next generation technology platform as part of this world-renowned team.”

Professor Sally Poppitt, University of Auckland, said “We are very pleased to have the opportunity to collaborate on this project with Associate Professors Leigh Ward and Lindsay Plank, both renowned experts in the assessment of body composition”

“At ImpediMed, we are committed to maximising the potential of scientific discoveries relevant to the development of new bioimpedance spectroscopy applications”, said ImpediMed President and CEO, Richard Carreon. “We look forward to working with this innovative group in the application of our technology focusing on improving people’s lives through better nutrition.”

For further information contact: Richard Carreon, ImpediMed CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

About ImpediMed
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit www.impedimed.com.au